What is the recommended treatment for pulmonary embolism, including anticoagulation regimens for hemodynamically stable patients, thrombolysis for massive pulmonary embolism, and inferior vena cava filter placement when anticoagulation is contraindicated?

Treatment of Pulmonary Embolism

For hemodynamically stable PE, start low-molecular-weight heparin (LMWH) or fondaparinux immediately and transition to a direct oral anticoagulant (DOAC) such as apixaban, rivaroxaban, edoxaban, or dabigatran rather than warfarin. 1

Initial Anticoagulation Strategy

Hemodynamically Unstable (High-Risk) PE

• Begin weight-adjusted unfractionated heparin (UFH) immediately without waiting for diagnostic confirmation: 80 U/kg IV bolus followed by 18 U/kg/h continuous infusion, targeting aPTT 1.5–2.5 times control. 1, 2
• UFH is preferred over LMWH in shock states because it can be rapidly reversed and is not renally cleared. 1, 2
• Adjust UFH dosing by aPTT-based nomogram:
  • aPTT <35 s: give 80 U/kg bolus, increase infusion by 4 U/kg/h
  • aPTT 35–45 s: give 40 U/kg bolus, increase infusion by 2 U/kg/h
  • aPTT 46–70 s: no change
  • aPTT 71–90 s: decrease infusion by 2 U/kg/h
  • aPTT >90 s: stop UFH for 1 hour, then reduce infusion by 3 U/kg/h 2

Hemodynamically Stable (Intermediate- or Low-Risk) PE

• LMWH or fondaparinux is strongly preferred over UFH because they have lower bleeding risk and require no laboratory monitoring. 1, 3, 4
• Start anticoagulation immediately in patients with high or intermediate clinical probability while diagnostic workup proceeds—do not delay treatment. 1, 3, 4
• Exception for severe renal impairment (CrCl <30 mL/min): use UFH instead of LMWH because LMWH is renally cleared. 1, 2

Thrombolytic Therapy

High-Risk (Massive) PE

• Systemic thrombolysis is indicated for PE presenting with cardiogenic shock or persistent hypotension (SBP <90 mmHg). 1, 2, 5
• Preferred regimen: alteplase (rtPA) 100 mg infused over 2 hours, or 50 mg IV bolus during cardiac arrest. 2, 5
• Alternative agents if rtPA unavailable:
  • Streptokinase 1.5 million IU over 2 hours
  • Urokinase 3 million IU over 2 hours 5

Intermediate-Risk (Submassive) PE

• Routine systemic thrombolysis is NOT recommended (Class III harm recommendation) in hemodynamically stable patients, even with right ventricular dysfunction. 1, 2, 6
• Rescue thrombolysis may be considered only if the patient deteriorates (develops hypotension, shock, or requires vasopressors) despite adequate anticoagulation. 1, 2

Low-Risk PE

• Thrombolysis should never be used. 2, 5

Alternative Reperfusion Strategies

When Thrombolysis Fails or Is Contraindicated

• Surgical pulmonary embolectomy is recommended for high-risk PE when thrombolysis is absolutely contraindicated, has failed, or the patient requires CPR. 1, 2, 5
• Catheter-directed embolectomy or fragmentation should be considered as an alternative to surgery when thrombolysis is unsuitable. 1, 2, 5
• ECMO may be considered in combination with surgical embolectomy or catheter-directed treatment for PE with refractory circulatory collapse or cardiac arrest. 1

Transition to Long-Term Oral Anticoagulation

DOAC vs. Warfarin

• DOACs (apixaban, rivaroxaban, edoxaban, or dabigatran) are preferred over vitamin K antagonists (VKAs) for all eligible patients. 1, 3, 4
• DOACs are contraindicated in:
  • Severe renal impairment (CrCl <30 mL/min)
  • Pregnancy and lactation
  • Antiphospholipid antibody syndrome 1, 3

When Using Warfarin

• Overlap warfarin with parenteral anticoagulation (LMWH or UFH) for at least 5 days and until INR is 2.0–3.0 on two consecutive days before stopping heparin. 1, 2
• Target INR is 2.5 (range 2.0–3.0). 1, 2
• Monotherapy with warfarin without initial heparin leads to a three-fold higher risk of recurrent VTE—never start warfarin alone. 2

Duration of Anticoagulation

• All patients require at least 3 months of therapeutic anticoagulation. 1, 2, 4
• Provoked PE (major transient risk factor such as surgery, trauma, immobilization): stop anticoagulation after 3 months. 1, 2, 4
• Unprovoked PE or persistent risk factors: continue anticoagulation indefinitely. 1, 2, 4
• Cancer-associated PE: LMWH is preferred for initial and long-term treatment, though apixaban, edoxaban, and rivaroxaban are effective alternatives. 2, 4

Inferior Vena Cava (IVC) Filters

• IVC filters should be considered in two specific situations:
  • Acute PE with absolute contraindications to anticoagulation
  • Recurrent PE despite therapeutic anticoagulation 1, 3
• Routine use of IVC filters is NOT recommended (Class III recommendation). 1, 3
• If a filter is placed, resume anticoagulation as soon as contraindications resolve to prevent filter thrombosis and DVT recurrence (21% vs. 12% without filter at 2 years). 1
• Long-term anticoagulation with target INR 2.0–3.0 is recommended after filter placement if not contraindicated. 1

Early Discharge and Outpatient Management

• Carefully selected low-risk PE patients should be considered for early discharge and home treatment if proper outpatient care and anticoagulation can be provided. 1

Common Pitfalls and Caveats

• Do not delay anticoagulation while awaiting imaging in patients with high or intermediate clinical probability—treat empirically. 1, 2, 3
• Avoid aggressive fluid boluses in PE-related hypotension because they increase right ventricular afterload and worsen right ventricular failure; use vasopressors (norepinephrine and/or dobutamine) instead. 1, 2, 5
• Do not use thrombolysis routinely in intermediate-risk PE—the bleeding risk outweighs benefit unless the patient deteriorates. 1, 2, 6
• Reassess all patients 3–6 months after acute PE; refer symptomatic patients with persistent perfusion defects to a pulmonary hypertension/CTEPH expert center. 3